Merck announced a collaboration with Mammoth Biosciences Inc., of South San Francisco, California, USA, for the development, scale-up and commercial production of Mammoth’s CRISPR-based SARS CoV-2 diagnostic test. Mammoth’s high-throughput systems will be compatible with both nasal swab and ... more
Merck has a good third quarter
Strong organic sales growth impacted by negative exchange rate effects
Merck generated very strong organic sales growth in the third quarter of 2018. However, this was impacted by negative exchange rate effects. Despite organic growth, EBITDA pre of the Group also declined in comparison with the year-earlier quarter owing to strong negative foreign exchange effects. Merck confirmed its forecast for the development of organic EBITDA pre for the full year 2018.
“2018 was a challenging year for Merck. We made future-oriented decisions that will lead to profitable growth as of 2019,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck. “In the third quarter, we generated strong organic sales growth across all three business sectors. In particular, Healthcare and Life Science performed well, delivering strong organic growth of nearly 10 percent.”
Group sales rose in the third quarter by 6.6% to € 3.7 billion (Q3 2017: € 3.5 billion). Organically, sales grew very strongly by 8.8%. The negative foreign exchange impact of –2.1% was primarily attributable to Latin American currencies such as the Argentinean peso and the Brazilian real.
EBITDA pre, the key financial indicator used to steer operating business, grew organically by 3.7%, thanks mainly to Healthcare and Life Science. However, significant negative foreign exchange effects of –9.5% caused EBITDA pre to decrease by –5.9% to € 963 million (Q3 2017: € 1,023 million). Group EBIT decreased by –43.1% to € 491 million (Q3 2017: € 862 million). Net income of the Merck Group fell in the third quarter by –47.2% to € 340 million (Q3 2017: € 644 million). The considerable declines in EBIT and Group net income are attributable to the gain of € 321 million on the divestment of the Biosimilars business reported in the previous year. Earnings per share pre declined by –7.7% to € 1.32 (Q3 2017: € 1.43)
- quarterly reports
Merck enhanced its advanced bioprocess portfolio through the acquisition of RESOLUTION Spectra Systems, a Meylan, France-based leader in bioprocess analytical monitoring. The company offers Raman spectroscopy analysis through its GMP-ready instrumentation and software. Financial details of ... more
Merck presented Professor David Alsteens (33), Catholic University of Louvain (UCLovain), Louvain-la-Neuve, Belgium with the 2019 Heinrich Emanuel Merck Award for Analytical Science. The award ceremony took place during the analytical conference Euroanalysis at Istanbul University in Turkey ... more
- 1Detect neurodegenerative diseases such as Alzheimer's by a simple eye scan?
- 2Fluorescence microscopy at highest spatial and temporal resolution
- 3The Mechanics of the Immune System
- 4Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis
- 5Quick look under the skin
- 6New ion trap to create the world's most accurate mass spectrometer
- 7How does your computer smell?
- 8Clocking electron movements inside an atom
- 9Sartorius closes 2020 with strong growth
- 10A clear path to better insights into biomolecules
- Simple to use device rapidly detects infectious diseases
- Fundamental regulation mechanism of proteins discovered
- Eppendorf achieves record revenue and best result in the company’s history in 2020
- New dimension for efficient laboratory work
- Researchers investigate structural changes in snap-frozen proteins